

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Pulmonary disease</b>				
Acute lung injury	Chemokine CC motif ligand 5 (RANTES; CCL5); platelet factor 4 (PF4; CXCL4)	Human and mouse studies suggest inhibiting the CCL5-CXCL4 interaction could help treat acute lung injury (ALI). In bronchial fluid from patients and lipopolysaccharide (LPS)-induced mouse models of ALI, levels of CCL5-CXCL4 heterodimers correlated with lung leukocyte infiltration. In mouse models of ALI, injection of CT-2009 (MKEY), a peptide antagonist of the CCL5-CXCL4 interaction, decreased levels of neutrophil elastase (NE; ELA-2), leukocyte infiltration and edema in the lung compared with injection of an inactive control peptide. Ongoing work from Carolus Therapeutics Inc. includes additional preclinical testing of CT-2009 to treat ALI and other pulmonary indications. NI-0701, a mAb that binds CCL5 from NovImmune S.A., is in Phase I testing to treat ischemia/reperfusion injury.	Patented by Aachen University; licensed to Carolus Therapeutics	Grommes, J. <i>et al. Am. J. Respir. Crit. Care Med.</i> ; published online Jan. 12, 2012; doi:10.1164/rccm.201108-1533OC <b>Contact:</b> Oliver Soehnlein, Ludwig Maximilian University of Munich, Munich, Germany e-mail: <a href="mailto:oliver.soehnlein@med-uni-muenchen.de">oliver.soehnlein@med-uni-muenchen.de</a>
<p><b>SciBX 5(5); doi:10.1038/scibx.2012.134</b>  <b>Published online Feb. 2, 2012</b></p>				